Bufuralol Hydrochloride: Expanding Applications in Human Intestinal Organoid-Based Cardiovascular Research

Introduction

The development of physiological in vitro models is rapidly advancing cardiovascular pharmacology research, particularly regarding the study of β-adrenergic modulation and pharmacokinetics of small molecule drugs. Bufuralol hydrochloride (CAS 60398-91-6) is a crystalline, non-selective β-adrenergic receptor antagonist with partial intrinsic sympathomimetic activity, which has become a valuable probe in these research domains. While its classical role has centered on β-adrenoceptor signaling pathway analysis and exercise-induced heart rate inhibition, recent trends in pharmacological studies are leveraging advanced human stem cell-derived organoid models to more accurately recapitulate human tissue responses (Saito et al., European Journal of Cell Biology, 2025).

This article presents a comprehensive overview of the application of Bufuralol hydrochloride in the context of human intestinal organoids, emphasizing its utility for β-adrenergic receptor blocker studies, membrane-stabilizing agent research, and cardiovascular disease modeling. In contrast to previous literature, we provide practical experimental considerations and novel insights into integrating organoid platforms with cardiovascular pharmacology endpoints.

Bufuralol Hydrochloride: Pharmacological Profile and Mechanisms

Bufuralol hydrochloride is characterized by its non-selective antagonism of β-adrenergic receptors and its capacity for partial intrinsic sympathomimetic activity. Its molecular weight is 297.8 (C16H23NO2·HCl), and it demonstrates solubility up to 15 mg/ml in ethanol or dimethyl formamide and 10 mg/ml in DMSO. The compound is notable for its membrane-stabilizing effects and capacity to induce tachycardia in animal models with depleted catecholamine stores, making it an important tool for dissecting the beta-adrenoceptor signaling pathway and for use in tachycardia animal model studies. Clinically, Bufuralol hydrochloride exhibits prolonged inhibition of exercise-induced heart rate elevation, a property that aligns it closely with first-line β-blockers such as propranolol, but with the added advantage of partial agonistic effects in certain contexts.

For cardiovascular pharmacology research, the dual action—antagonist and partial agonist—enables nuanced investigation of β-adrenergic modulation, receptor desensitization, and downstream signaling events. The membrane-stabilizing properties further suggest utility in arrhythmia and myocardial excitability models, extending its relevance to broader cardiovascular disease research.

Human Intestinal Organoids: Transforming Pharmacokinetic and Disease Modeling

Traditional pharmacokinetic studies have relied on animal models or immortalized cell lines such as Caco-2 cells, which often fail to fully recapitulate human drug metabolism due to species differences and limited expression of key enzymes, including CYP3A4. Recent research by Saito and colleagues (2025) demonstrates that human induced pluripotent stem cell (hiPSC)-derived intestinal organoids (IOs) can serve as a robust in vitro platform for drug metabolism and absorption studies. These organoids faithfully differentiate into mature intestinal epithelial cells, including enterocytes with functional P-glycoprotein (P-gp) and cytochrome P450 3A (CYP3A) activity, critical for evaluating oral bioavailability and first-pass metabolism.

The integration of such organoid models in β-adrenergic modulation studies using Bufuralol hydrochloride offers several advantages:

• Human relevance: hiPSC-IOs express human-specific drug metabolizing enzymes and transporters, reducing translational gaps seen in animal studies.
• Complexity: 3D architecture and cellular diversity allow for more physiologically accurate assessment of drug absorption, metabolism, and potential off-target effects.
• Scalability and reproducibility: As shown by Saito et al., IOs can be propagated long-term, cryopreserved, and differentiated on demand, supporting standardized high-throughput screening.

Experimental Considerations for Using Bufuralol Hydrochloride in Organoid-Based Studies

Applying Bufuralol hydrochloride in IO-based research requires attention to its chemical properties and experimental endpoints:

• Compound handling: Bufuralol hydrochloride solutions should be freshly prepared in compatible solvents (ethanol, DMSO, or DMF) at recommended concentrations. Long-term storage of solutions is discouraged due to stability concerns; aliquots should be stored at -20°C.
• Metabolic profiling: The capacity of IO-derived enterocytes to metabolize Bufuralol hydrochloride via CYP3A4 can be leveraged to assess drug-drug interactions, transporter activity (e.g., P-gp), and inter-individual variability, especially when using patient-specific hiPSCs.
• Pharmacodynamic endpoints: β-adrenergic receptor signaling can be interrogated through cAMP accumulation assays, gene expression profiling, and functional readouts such as epithelial barrier integrity or contractility in microfluidic gut-on-chip formats.
• Integration with cardiovascular models: Co-culture platforms combining intestinal organoids and cardiac spheroids or engineered heart tissues can be used to study systemic effects of oral β-blockers, including Bufuralol hydrochloride, on downstream cardiac function.

Novel Insights: Bufuralol Hydrochloride as a Probe in Intestinal-Cardiac Axis Research

Recent interest in the gut-heart axis highlights the importance of intestinal metabolism in modulating cardiovascular drug action. Bufuralol hydrochloride, with its clear-cut β-adrenergic receptor blockade and partial agonist activity, presents an excellent candidate for dissecting how intestinal first-pass effects alter pharmacodynamics in the heart. For example, leveraging hiPSC-IOs to measure CYP3A4-mediated metabolism of Bufuralol hydrochloride, followed by exposure of the resulting metabolites to human iPSC-derived cardiomyocytes, can clarify the contribution of gut metabolism to systemic efficacy and side effect profiles. This approach is particularly relevant for cardiovascular disease research, where inter-individual differences in metabolism may influence drug response, arrhythmogenic risk, or therapeutic window.

Moreover, Bufuralol hydrochloride's membrane-stabilizing actions can be evaluated in the context of intestinal epithelial barrier models to investigate potential secondary effects on gut integrity or permeability, which may have downstream consequences for systemic inflammation and cardiovascular risk. This represents an underexplored intersection between pharmacokinetics and disease pathophysiology.

Methodological Guidance: Designing β-Adrenergic Modulation Studies with Bufuralol Hydrochloride

For researchers aiming to utilize Bufuralol hydrochloride in advanced in vitro models, the following experimental strategies are recommended:

• Employ dose-ranging studies starting from low micromolar concentrations, guided by known pharmacokinetics and solubility limits.
• Utilize parallel measurements of parent compound and metabolites via LC-MS/MS to quantify metabolism in IOs.
• Assess β-adrenergic receptor function before and after drug exposure using both molecular (e.g., qPCR of β1/β2-AR subunits) and functional assays (e.g., cAMP response, transepithelial electrical resistance).
• Incorporate patient-derived hiPSC-IOs to model genetic variability and disease-specific responses, supporting personalized medicine approaches.
• Where feasible, integrate organoid data with computational pharmacokinetic-pharmacodynamic (PK-PD) modeling to predict in vivo drug behavior.

Future Perspectives: Integrating Organoid and Cardiovascular Platforms

The application of Bufuralol hydrochloride in human IO models is poised to advance β-adrenergic modulation studies beyond traditional endpoints. The ability to recapitulate human drug metabolism, absorption, and tissue-specific responses in vitro provides a foundation for more predictive cardiovascular pharmacology research. Looking ahead, multi-organoid systems encompassing gut, liver, and heart tissues—linked via microfluidics—may enable true systems-level pharmacological investigations, with Bufuralol hydrochloride serving as a reference compound for β-adrenergic receptor blocker studies and cardiovascular disease modeling.

Conclusion

Bufuralol hydrochloride represents a versatile tool for cardiovascular pharmacology research, particularly as a non-selective β-adrenergic receptor antagonist with partial intrinsic sympathomimetic activity. Its integration into human induced pluripotent stem cell-derived intestinal organoid models, as described by Saito et al. (2025), opens new avenues for studying the interplay between drug metabolism, β-adrenergic signaling, and systemic cardiovascular effects. This approach not only refines our understanding of the beta-adrenoceptor signaling pathway but also supports the development of more predictive, human-relevant disease models.

While earlier works such as "Bufuralol Hydrochloride in β-Adrenergic Modulation: Insights from Traditional Models" have focused primarily on classic in vitro and animal approaches, the present article extends the landscape by providing methodological guidance and novel perspectives on the use of Bufuralol hydrochloride within advanced human organoid platforms. This integration of organoid technology with cardiovascular endpoints represents a critical evolution in β-adrenergic modulation studies and paves the way for more precise, translational research in drug development.